Affibody-based molecular probe 99mTc-(HE)3ZHER2:V2 for non-invasive HER2 detection in ovarian and breast cancer xenografts

被引:0
|
作者
Hu, Xianwen [1 ]
Hu, Hongyu [1 ]
Li, Dandan [2 ]
Wang, Pan [1 ]
Cai, Jiong [1 ]
机构
[1] Zunyi Med Univ, Affiliated Hosp, Dept Nucl Med, 149 Dalian Rd, Zunyi 563003, Peoples R China
[2] Zunyi Hosp Tradit Chinese Med, Dept Obstet, Zunyi 563003, Guizhou, Peoples R China
来源
OPEN MEDICINE | 2024年 / 19卷 / 01期
关键词
human epidermal growth factor receptor 2; affibody; SPECT imaging; ovarian cancer; Tc-99m; BIODISTRIBUTION;
D O I
10.1515/med-2024-1027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose- This study aimed to assess the biodistribution and bioactivity of the affibody molecular probe Tc-99m-(HE)(3)Z(HER2:V2), prepared by genetic recombination, and to investigate its potential for targeted human epidermal growth factor receptor 2 (HER2) imaging in SKOV3 ovarian cancer and MDA-MB-361 breast cancer xenografts. Methods- Affibody molecules were generated through genetic recombination. The radiochemical purity of the Tc-99m-labeled HER2 affibody was determined using reverse phase high performance liquid chromatography (RP-HPLC). Evaluation of HER2 affinity in SKOV3 ovarian cancer cells and MDA-MB-361 breast cancer cells (HER2-positive) was conducted by calculating equilibrium dissociation constants. Biodistribution of the Tc-99m-labeled affibody molecular probe was assessed in Balb/c mice bearing SKOV3 tumors. Tumor targeting specificity was evaluated in Balb/c mice using SKOV3, MDA-MB-361, and AT-3 (HER2-negative) xenografts. Results- Affibody (HE)(3)Z(HER2:V2), generated through recombinant gene expression, was successfully labeled with Tc-99m, achieving a radiochemical purity of (96.0 +/- 1.7)% (n = 3) as determined by RP-HPLC. This molecular probe exhibited specific binding to HER2-positive SKOV3 cells, demonstrating intense radioactive uptake. Biodistribution analysis showed rapid accumulation of Tc-99m-(HE)(3)Z(HER2:V2) in HER2-positive tumors post-administration, primarily clearing through the urinary system. Single-photon emission computed tomography imaging conducted 1-3 h after intravenous injection of Tc-99m-(HE)(3)Z(HER2:V2) into HER2-positive SKOV3 and MDA-MB-361 nude mouse models confirmed targeted uptake of the molecular probe by the tumors. Conclusions- The molecular probe Tc-99m-(HE)(3)Z(HER2:V2) developed in this study effectively targets HER2 for imaging HER2-positive SKOV3 and MDA-MB-361 xenografts in vivo. It exhibits rapid blood clearance without evident toxic effects, suggesting its potential as a valuable marker for detecting HER2 expression in tumor cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Radiolabelled Trastuzumab PET/CT imaging: a promising non-invasive tool for the in vivo assessment of HER2 status in breast cancer patients
    Lorusso, Margherita
    Scolozzi, Valentina
    Taralli, Silvia
    Caldarella, Carmelo
    Altini, Corinna
    Rubini, Giuseppe
    Calcagni, Maria Lucia
    CLINICAL AND TRANSLATIONAL IMAGING, 2020, 8 (02) : 95 - 105
  • [32] A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer
    Alhuseinalkhudhur, Ali
    Lindman, Henrik
    Liss, Per
    Sundin, Tora
    Frejd, Fredrik Y.
    Hartman, Johan
    Iyer, Victor
    Lubberink, Mark
    Velikyan, Irina
    Sorensen, Jens
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Radiolabelled Trastuzumab PET/CT imaging: a promising non-invasive tool for the in vivo assessment of HER2 status in breast cancer patients
    Margherita Lorusso
    Valentina Scolozzi
    Silvia Taralli
    Carmelo Caldarella
    Corinna Altini
    Giuseppe Rubini
    Maria Lucia Calcagni
    Clinical and Translational Imaging, 2020, 8 : 95 - 105
  • [34] Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments
    Tang, Y
    Scollard, D
    Chen, P
    Wang, J
    Holloway, C
    Reilly, RM
    NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (05) : 427 - 432
  • [35] Direct clinical comparison of scaffold proteins [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 for imaging of HER2-positive breast cancer
    Tolmachev, Vladimir
    Bragina, Olga
    Schulga, Alexey
    Hober, Sophia
    Borin, Jesper
    Deyev, Sergey
    Chernov, Vladimir
    NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S155 - S155
  • [36] High sensitivity saliva-based biosensor in detection of breast cancer biomarkers: HER2 and CA15-3
    Wan, Hsiao-Hsuan
    Zhu, Haochen
    Chiang, Chao-Ching
    Li, Jian-Sian
    Ren, Fan
    Tsai, Cheng-Tse
    Liao, Yu-Te
    Neal, Dan
    Esquivel-Upshaw, Josephine F.
    Pearton, Stephen J.
    JOURNAL OF VACUUM SCIENCE & TECHNOLOGY B, 2024, 42 (02):
  • [37] A direct comparison of the diagnostic efficacy of alternative scaffold- based radiopharmaceuticals [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in patients with HER2-positive breast cancer
    Bragina, O. D.
    Deyev, S. M.
    Garbukov, E. Yu
    Goldberg, V. E.
    Chernov, V. I.
    Tolmachev, V. M.
    BYULLETEN SIBIRSKOY MEDITSINY, 2023, 22 (03): : 6 - 13
  • [38] Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer
    Larkina, Mariia
    Plotnikov, Evgenii
    Bezverkhniaia, Ekaterina
    Shabanova, Yulia
    Tretyakova, Maria
    Yuldasheva, Feruza
    Zelchan, Roman
    Schulga, Alexey
    Konovalova, Elena
    Vorobyeva, Anzhelika
    Garousi, Javad
    Graslund, Torbjorn
    Belousov, Mikhail
    Tolmachev, Vladimir
    Deyev, Sergey
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [39] Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer
    Bragina, Olga
    Chernov, Vladimir
    Schulga, Alexey
    Konovalova, Elena
    Hober, Sophia
    Deyev, Sergey
    Sorensen, Jens
    Tolmachev, Vladimir
    CANCERS, 2023, 15 (12)
  • [40] Development of Sybr Green I-Based Melting Curve Method for HER2(I655V) Polymorphism Detection in Breast Cancer
    Budiarto, Bugi R.
    Harahap, Wirsma A.
    Desriani
    MAKARA JOURNAL OF HEALTH RESEARCH, 2016, 20 (02): : 29 - 34